Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports
(Reuters) -Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for more than $70 per share, Bloomberg News reported, citing a person familiar with the matter who said an announcement could come as early as Sunday. Novartis and Avidity did not immediately respond to requests for comment about the report. Novartis has been actively …










